Canadian Phytopharmaceuticals Corporation (CPC) was established in Richmond, British Columbia, Canada.
Almost immediately after its inception, CPC developed multiple High Performance Liquid Chromatography (HPLC) methods. CPC has positioned itself as a research based company from the beginning.
After several years of ginseng research, our research team proposed, for the first time, the importance of the ratio of major ginsenosides in different plants of the ginseng plant. This provided the foundation work for the future HPLC fingerprinting.
For the first time in the industry, the concept of Standardization in the quality control of botanical extracts.
Established a database of HPLC profiles for some of the important medicinal herbs including Kava Kava, St. John's Wort, Cat's Claw, Goldenseal, Echinacea and North American Ginseng, among others.
Ginseng Evaluation Program - a comprehensive collaborative research project involving the American Botanical Council, University of Illinois at Chicago and University of Ottawa.
The House of Commons Standing Committee on Health engages in broad consultations and ultimately recommends a distinct regulatory framework for natural health products. Its report "Natural Health Products: A New Vision" is tabled in the House of Commons.
The first International Conference on the Standardization and Internationalization of Phytomedicines held in Beijing China, which was co-chaired and co-organized by the then Chinese State Drug Administration (SDA) and Canadian Phytopharmaceuticals Corporation.
The Natural Health Product Regulations (NHPR) come into effect on January 1, 2004. For the first time in Canada, NHPs have their own unique regulatory system designed specifically for this diverse category of products. The NHPR contains specific requirements for product licensing, site licensing, Good Manufacturing Practices (GMP) and clinical trials.
The NHPR set a two-year phase-in period for companies that were in operation at the time to become GMP compliant by obtaining a Site Licence. CPC was among the first group of companies that obtained site licence from NHPD.
Goldenseal Industrial Standard Project with the National Research Centre Canada (NRC).
CPC moved into its current 30,000 square foot manufacturing facility which was specifically designed and built in accordance with the GMP requirements under the new Natural Health Product Regulations.
Adopted the newly developed Rapid Resolution Liquid Chromatography (RRLC) technology and established relevant RRLC profiles for the quality control of a number of medicinal ingredients including Epimedium, Rhodiola, Siberian Ginseng, North American Ginseng etc. It dramatically decreased the analytical time and improved testing efficiency compared to the conventional HPLC method.
A joint, collaborative research laboratory was established between CPC, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and the Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences.
CPC's research team published a series of scientific research papers “Rapid resolution liquid chromatography (RRLC) analysis and studies on the stability of Shuang-Huang-Lian preparations” published in the Journal of Pharmaceutical and Biomedical Analysis. This publication, together with other recent scientific publications cements CPC’s leading edge position in both the industry and academic spheres on the RRLC technologies in identifying multiple chemical constituents in a formulated product.
The new ‘CANPHY®’ brand, registered worldwide, is launched in order to market the premium quality botanical extracts produced by CPC.